Arkolith/Insider Trading/ELVN/Form 4

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Jan 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.5M
Net Open-Market Flow
-$3.5M
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 9, 2026Sell(S)41K$24.90$1.0M815K
Jan 9, 2026Sell(S)50K$29.13$1.5M765K
Jan 8, 2026Sell(S)8K$20.13$151K890K
Jan 8, 2026Sell(S)34K$24.92$842K856K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001967150-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML